Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update
Zentalis Pharmaceuticals, Inc. - common stock (ZNTL)
Company Research
Source: GlobeNewswire
Announced initial data on ZN-c3 in combination with chemotherapy in advanced ovarian cancer and interim data on ZN-c3 in uterine serous carcinoma (USC) at AACR Received a $25 million equity investment from Pfizer, with plans to jointly advance clinical development of ZN-c3, and expanded its Scientific Advisory Board with the addition of Pfizer’s Dr. Adam Schayowitz Initiated a potentially registrational Phase 1/2 study of ZN-d5 in patients with relapsed or refractory light chain (AL) amyloidosis Cash runway extended into Q1 2024, with Pfizer’s equity investment and budget reallocation NEW YORK and SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the first quarter ended March 31, 2022 and highlighted recent corporate accomplishments. “In th
Show less
Read more
Impact Snapshot
Event Time:
ZNTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZNTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZNTL alerts
High impacting Zentalis Pharmaceuticals, Inc. - common stock news events
Weekly update
A roundup of the hottest topics
ZNTL
News
- Susan G. Komen® Strengthens Leadership with Strategic Appointments to Board of Directors [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price [Yahoo! Finance]Yahoo! Finance
- Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $46.00 price target on the stock.MarketBeat
- Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet [Yahoo! Finance]Yahoo! Finance
ZNTL
Earnings
- 11/6/23 - Beat
ZNTL
Sec Filings
- 2/29/24 - Form S-8
- 2/29/24 - Form S-3ASR
- 2/27/24 - Form 10-K
- ZNTL's page on the SEC website